Literatura científica selecionada sobre o tema "Psychotropic drugs – pharmacokinetics"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Índice
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Psychotropic drugs – pharmacokinetics".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Psychotropic drugs – pharmacokinetics"
Fernandes Santos, C., e R. Gomes. "Specificities of the Use of Psychotropic Drugs in Bariatric Surgery". European Psychiatry 65, S1 (junho de 2022): S478—S479. http://dx.doi.org/10.1192/j.eurpsy.2022.1216.
Texto completo da fonteBOURIN, M., e A. COUETOUX DU TERTRE. "PHARMACOKINETICS OF PSYCHOTROPIC DRUGS IN CHILDREN." Clinical Neuropharmacology 15 (1992): 224A—225A. http://dx.doi.org/10.1097/00002826-199201001-00117.
Texto completo da fonteSit, D. K., J. M. Perel, J. Helsel e K. L. Wisner. "Pharmacokinetics of psychotropic drugs in pregnancy". Neurotoxicology and Teratology 29, n.º 3 (maio de 2007): 411. http://dx.doi.org/10.1016/j.ntt.2007.03.051.
Texto completo da fonteBurns, Alistair, e Robert Baldwin. "Prescribing psychotropic drugs for the elderly". Advances in Psychiatric Treatment 1, n.º 1 (setembro de 1994): 23–31. http://dx.doi.org/10.1192/apt.1.1.23.
Texto completo da fonteMarazziti, Donatella, Stefano Baroni, Michela Picchetti, Armando Piccinni, Marina Carlini, Elena Vatteroni, Valentina Falaschi, Amedeo Lombardi e Liliana Dell'Osso. "Pharmacokinetics and pharmacodinamics of psychotropic drugs: effect of sex". CNS Spectrums 18, n.º 3 (4 de fevereiro de 2013): 118–27. http://dx.doi.org/10.1017/s1092852912001010.
Texto completo da fonteBaumann, P. "JS01-01 - Pharmacokinetics of psychotropic drugs - keys for treatments’ improvements". European Psychiatry 26, S2 (março de 2011): 1995. http://dx.doi.org/10.1016/s0924-9338(11)73698-7.
Texto completo da fontePichini, Simona, Esther Papaseit, Xavier Joya, Oriol Vall, Magí Farré, Oscar Garcia-Algar e Rafael de laTorre. "Pharmacokinetics and Therapeutic Drug Monitoring of Psychotropic Drugs in Pediatrics". Therapeutic Drug Monitoring 31, n.º 3 (junho de 2009): 283–318. http://dx.doi.org/10.1097/ftd.0b013e31819f3328.
Texto completo da fonteIannaccone, Teresa, Carmine Sellitto, Valentina Manzo, Francesca Colucci, Valentina Giudice, Berenice Stefanelli, Antonio Iuliano, Giulio Corrivetti e Amelia Filippelli. "Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters". Pharmaceuticals 14, n.º 3 (1 de março de 2021): 204. http://dx.doi.org/10.3390/ph14030204.
Texto completo da fonteMoschny, Nicole, Gudrun Hefner, Renate Grohmann, Gabriel Eckermann, Hannah B. Maier, Johanna Seifert, Johannes Heck et al. "Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics". Pharmaceuticals 14, n.º 6 (27 de maio de 2021): 514. http://dx.doi.org/10.3390/ph14060514.
Texto completo da fonteTelles-Correia, Diogo, António Barbosa, Helena Cortez-Pinto, Carlos Campos, Nuno B. F. Rocha e Sérgio Machado. "Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity". World Journal of Gastrointestinal Pharmacology and Therapeutics 8, n.º 1 (2017): 26. http://dx.doi.org/10.4292/wjgpt.v8.i1.26.
Texto completo da fonteTeses / dissertações sobre o assunto "Psychotropic drugs – pharmacokinetics"
Dos, Santos Pereira João Nuno [Verfasser], Jürgen [Akademischer Betreuer] Brockmöller, Gerhard [Akademischer Betreuer] Burckhardt e Uwe-Karsten [Akademischer Betreuer] Hanisch. "The role of membrane transporters in the pharmacokinetics of psychotropic drugs: in vitro studies with special focus on organic cation transporters / João Nuno Dos Santos Pereira. Gutachter: Gerhard Burckhardt ; Uwe-Karsten Hanisch. Betreuer: Jürgen Brockmöller". Göttingen : Niedersächsische Staats- und Universitätsbibliothek Göttingen, 2015. http://d-nb.info/1068056185/34.
Texto completo da fonteChapy, Hélène. "Identification fonctionnelle et moléculaire d'un transporteur de psychotropes et substances d'abus". Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015PA05P603.
Texto completo da fonteThe central nervous system is a privilege organ protected by histological barriers between the blood and the nervous tissue. The blood-brain barrier (BBB) and the blood-retinal barrier (BRB) separate cerebral parenchyma and retina from the circulating blood and both express tight junctions and membrane transporters, allowing a precise regulation of the exchanges between the blood and nervous tissues. We studied a new cationic transporter functionally evidenced at the mouse BBB. This molecularly unknown transporter belong to the solute carrier super family (SLC) and is a proton antiporter. It could constitute a new actor in the cerebral permeability and may be a new brain access pathway. First, we worked on the functional identification studying new substrates and new localization. Psychotropic brain transport was studied in vivo by brain in situ perfusion on mouse and in vitro with human immortalized endothelial cells (hCMEC/D3). We showed that cocaine brain entry depends on passive diffusion but also mainly on a proton antiporter. Brain entry rate of drugs of abuse is associated with modulation of addiction liability, making this transporter a new component of brain entry of cocaine, and also nicotine and some amphetamines such as ecstasy and MDPV. This proton antiporter appears to be a new potential target in addiction. Various chemical entities interact with this transporter; however concentrations used to inhibit the transporter are much higher than the one possibly found in the blood. In order to help find or design new selective and potent inhibitors, we developed a pharmacophore model of the proton antiporter inhibitors using in vitro data and the FLAPpharm approach. The model predicts well new possible inhibitors of this transporter. We also studied the impact of the ABC transporters and the proton antiporter at the BBB and the BRB using specific or multi-specific substrates such as verapamil. The proton antiporter is functionally expressed at the BRB and transports clonidine, DPH and verapamil. However, for the multi-specific (P-gp and SLC) compound verapamil, influx transport by the proton antiporter is visible at the BBB only when P-gp efflux is neutralized. On the contrary, at the BRB, the proton antiporter influx is always visible. This is certainly due to the lower impact (by 6.3 fold) of P-gp at the BRB compared to the BBB. These results show the difficulty to predict the functional impact of a transporter for multi-specific compounds and a probable transport prioritization. Finally we worked on the molecular identification of the proton antiporter using a photolabeling method. This work evidenced the importance of the proton antiporter in the brain distribution of psychotropic and drugs of abuse and opened toward new perspectives in addiction and transport comprehension
Santos, Pereira João Nuno dos. "The role of membrane transporters in the pharmacokinetics of psychotropic drugs: in vitro studies with special focus on organic cation transporters". Doctoral thesis, 2015. http://hdl.handle.net/11858/00-1735-0000-0022-5DB2-5.
Texto completo da fonteLivros sobre o assunto "Psychotropic drugs – pharmacokinetics"
N, Musa Mahmoud, ed. Pharmacokinetics and therapeutic monitoring of psychiatric drugs. Springfield, Ill., U.S.A: C.C. Thomas, 1993.
Encontre o texto completo da fonteJ, Ferrando Stephen, Levenson James L e Owen James A. 1949-, eds. Clinical manual of psychopharmacology in the medically ill. Washington, DC: American Psychiatric Pub., 2010.
Encontre o texto completo da fonteMrazek, David. Psychiatric pharmacogenomics. New York: Oxford University Press, 2010.
Encontre o texto completo da fonteTrachsel, Daniel. Psychedelische Chemie. 2a ed. Solothurn: Nachtschatten Verlag, 2000.
Encontre o texto completo da fonteRay, Oakley Stern. Drugs, society & human behavior. 4a ed. St. Louis: Times Mirror/Mosby College Pub., 1987.
Encontre o texto completo da fonteCharles, Ksir, ed. Drugs, society & human behavior. 7a ed. St. Louis: Mosby, 1996.
Encontre o texto completo da fonteRay, Oakley Stern. Drugs, society & human behavior. 5a ed. St. Louis: Times Mirror/Mosby College Pub., 1990.
Encontre o texto completo da fonteRay, Oakley Stern. Drugs, society & human behavior. 6a ed. St. Louis: Mosby Year Book, 1993.
Encontre o texto completo da fonteRay, Oakley Stern. Drugs, society, and human behavior. 8a ed. Boston: WCB/McGraw-Hill, 1999.
Encontre o texto completo da fonteRay, Oakley Stern. Drugs, society, and human behavior. 9a ed. Boston: McGraw-Hill, 2002.
Encontre o texto completo da fonteCapítulos de livros sobre o assunto "Psychotropic drugs – pharmacokinetics"
Guimarães, Marília Zaluar Passos, e Gilda Ângela Neves. "Pharmacology of Drugs of Abuse: Pharmacokinetics and Pharmacodynamics of Psychotropic Compounds". In Drugs and Human Behavior, 109–27. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-62855-0_8.
Texto completo da fonteBrøsen, K., e L. F. Gram. "Pharmacokinetic and Clinical Significance of Genetic Variability in Psychotropic Drug Metabolism". In Clinical Pharmacology in Psychiatry, 192–200. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-74430-3_20.
Texto completo da fonteAronson, J. K. "General principles of drug therapy in psychiatry". In New Oxford Textbook of Psychiatry, 1168–77. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199696758.003.0151.
Texto completo da fonteMadhusoodanan, Subramoniam, Marina Tsoy-Podosenin, Leah R. Steinberg e Nitin Tandan. "Drug interactions involving psychotropic drugs". In Mental Disorders in Primary Care. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198746638.003.0021.
Texto completo da fontePollock, Bruce G. "Pharmacokinetics and Pharmacodynamics In Late Life". In Late-Life Depression, 185–91. Oxford University PressNew York, NY, 2004. http://dx.doi.org/10.1093/oso/9780195152746.003.0015.
Texto completo da fonteHarrison, Paul, Philip Cowen, Tom Burns e Mina Fazel. "Drugs and other physical treatments". In Shorter Oxford Textbook of Psychiatry, 709–76. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198747437.003.0025.
Texto completo da fonteVitiello, Benedetto. "Clinical trials methodology and design issues". In Pediatric Psychopharmacology: Principles and Practice, 712–24. Oxford University PressNew York, NY, 2002. http://dx.doi.org/10.1093/oso/9780195141733.003.0053.
Texto completo da fonteGYÜRE, K. I., T. SZENTENDREI, M. I. K. FEKETE e A. Z. RÓNAI. "THE EFFECT OF NOVEL PSYCHOTROPIC DRUGS ON RAT BRAIN DOPAMINE- AND ALPHA-ADRENERGIC RECEPTOR BINDING IN VITRO". In Receptors and Centrally Acting Drugs Pharmacokinetics and Drug Metabolism, 309–12. Elsevier, 1986. http://dx.doi.org/10.1016/b978-0-08-034191-0.50047-7.
Texto completo da fonteGutierrez, Cynthia A., e Barry S. Fogel. "Pharmacokinetics of Psychotropic Drugs in the Context of General Medical Illness". In Psychiatric Care of the Medical Patient, 448–78. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199731855.003.0022.
Texto completo da fonteLaughren, Thomas P. "Regulatory issues". In Pediatric Psychopharmacology: Principles and Practice, 725–36. Oxford University PressNew York, NY, 2002. http://dx.doi.org/10.1093/oso/9780195141733.003.0054.
Texto completo da fonteTrabalhos de conferências sobre o assunto "Psychotropic drugs – pharmacokinetics"
Schoretsanitis, G. "Establishing therapeutic drug monitoring to routinely assess pharmacokinetic changes for psychotropic medications prescribed during pregnancy and lactation". In XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP. Georg Thieme Verlag, 2024. http://dx.doi.org/10.1055/s-0044-1779547.
Texto completo da fonte